SCM
COGT icon

Soleus Capital Management’s Cogent Biosciences COGT Stock Holding History

Soleus Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$385K Sell
10,000
-110,000
-92% -$4.06M 0.02% 84
2025
Q4 		$4.26M Buy
+120,000
New +$3.37M 0.16% 71
2020
Q4 		– Sell
-11,975
Closed -$112K – 68
2020
Q3 		$112K Buy
+11,975
New +$125K 0.06% 63

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Soleus Capital Management's COGT Position: Q1 2026 in Review

Soleus Capital Management reduced its Cogent Biosciences (COGT) stake by 92% in Q1 2026, selling an estimated $4.06M and leaving 10,000 shares worth $385K. The position accounts for 0.02% of the portfolio, ranked #84.

Soleus Capital Management first reported a position in COGT in Q3 2020 and has held it in 3 quarters since. The position peaked at $4.26M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Soleus Capital Management held 10,000 shares of Cogent Biosciences worth $385K as of Q1 2026.
  • Soleus Capital Management sold 110,000 Cogent Biosciences shares in Q1 2026, an estimated $4.06M.
  • Cogent Biosciences made up 0.02% of Soleus Capital Management's portfolio in Q1 2026, its #84 holding.
  • Soleus Capital Management first reported a position in Cogent Biosciences in Q3 2020 and has held it in 3 quarters since.
  • Soleus Capital Management's Cogent Biosciences position peaked at $4.26M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.